News for Merck Stock (MRK)

Is a Surprise Coming for Merck & Co. (MRK) This Earnings Season?

Zacks Investment Research • 10/25/23

Earnings Previews: Reports Coming Thursday Morning From Comcast, Merck, UPS, Valero Energy

24/7 Wall Street • 10/24/23

Merck & Co. Inc. (MRK) Merck & Co. Announced Collaboration with Daiichi Sankyo and ESMO Investor Event (Transcript)

Seeking Alpha • 10/23/23

How This New Merck Regimen Could 'Rewrite Textbooks' In Cancer Treatment — And Bolster 4 Stocks

Investors Business Daily • 10/23/23

Daiichi Sankyo: Merck Partnership Poises Both Companies For ADC Expansion

Seeking Alpha • 10/23/23

Merck discontinues some cancer drug development with China's Sichuan Kelun

Reuters • 10/23/23

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Versus Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

Business Wire • 10/22/23

Merck's WELIREG® (belzutifan) Significantly Improved Progression-Free Survival and Objective Response Rates Versus Everolimus in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

Business Wire • 10/21/23

Merck (MRK) Inks Deal With Daiichi to Develop Cancer Drugs

Zacks Investment Research • 10/20/23

Merck and Daiichi Sankyo Strike Cancer Drug Deal Worth Up to $22 Billion

Investopedia • 10/20/23

Merck's KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy Significantly Improved Progression-Free Survival (PFS) Versus Concurrent Chemoradiotherapy Alone in Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer

Business Wire • 10/20/23

7 Healthcare Stocks to invest in for a Healthy Future

InvestorPlace • 10/20/23

Merck's Keytruda shows positive results in confirmatory trial as treatment for rare form of esophageal cancer

Market Watch • 10/20/23

Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Improvement in Pathological Complete Response (pCR) Rate as Neoadjuvant Therapy Versus Chemotherapy in High-Risk, Early-Stage ER+/HER2- Breast Cancer

Business Wire • 10/20/23

KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Progression-Free Survival (PFS) Versus Trastuzumab and Chemotherapy in First-Line HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Business Wire • 10/20/23

KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by 28% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)

Business Wire • 10/20/23

Daiichi Sankyo shares jump on multibillion-dollar drug development deal with Merck

Market Watch • 10/20/23

Daiichi Sankyo and Merck team up on $22 bln collaboration for Sankyo's antibody drug conjugates

Reuters • 10/19/23

Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs

Business Wire • 10/19/23

Merck (MRK) Gets CHMP Nod for Expanded Use of Antiviral Drug

Zacks Investment Research • 10/18/23

Merck's (MRK) Keytruda Gets FDA Nod in Sixth NSCLC Indication

Zacks Investment Research • 10/17/23

EU regulator backs Merck's viral infection drug

Reuters • 10/17/23

Merck Receives Positive EU CHMP Opinion for PREVYMIS® for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease

Business Wire • 10/17/23

FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With Resectable (T≥4 cm or N+) NSCLC in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as a Single Agent as Adjuvant Treatment After Surgery

Business Wire • 10/16/23

Merck's Keytruda gets U.S. FDA's nod for expanded use in lung cancer

Reuters • 10/16/23